Dermagnostix announces acquisition and continuation of the fluorescence detector technology of Dialunox as of July 1st 2025

Freiburg im Breisgau, 05.05.2025 – The Dermagnostix GmbH from Freiburg, specialized on the development of molecular diagnostic tests for dermatology,…

Dermagnostix kündigt Übernahme und Fortführung der Fluoreszenzdetektor Technologie von Dialunox zum 01.07.2025 an

Freiburg im Breisgau, 05.05.2025 – Die Dermagnostix GmbH aus Freiburg, spezialisiert auf die Entwicklung molekulardiagnostischer Tests für dermatologische Fragestellungen, erweitert…

Dermagnostix CEO Prof. Dr. Natalie Garzorz-Stark Wins Innovation Award Dermatology by BVDD e.V.

Dermagnostix CEO and Co-founder Prof. Dr. Natalie Garzorz Stark has been awared the Innovation Award Dermatology by Bundesverband der Deutschen…

State Parliament President Muhterem Aras and Member of Parliament Nadyne Saint-Cast Visit Dermagnostix in Freiburg

The President of the Baden-Württemberg Parliament, Muhterem Aras, and Nadyne Saint-Cast, Member of Parliament, recently visited Dermagnostix at its offices…

First On-Demand Webinar “Pattern in Inflammatory Skin Diseases”

We are excited to announce the launch of our new webinar series “Beyond the Surface: Revolutionizing Skin Diagnostics Through Molecular…

Dermagnostix at MEDICA 2024

Dermagnostix has been selected by the EIC- International Fairs 3.0 Programme as a startup with groundbreaking innovation for MEDICA 2024…

Dermagnostix on tour in June 2024

June was packed with exciting events and we had a great time exhibiting at ADH annual meeting in Göttingen as…

Dermagnostix GmbH announces product launch of PsorX®-LabDisk (CE-IVD) after successful pilot customer phase

Dermagnostix announces the official launch of the PsorX®-LabDisk. After the market entry with CE-IVD certification in 2022 and a following…